Given the rate of scientific advances over the past 20 years, it is difficult for practicing radiation oncologists to stay abreast of the latest drugs, their targets and mechanisms of action.

The use of SABR is well established in many cancers, however, its application within kidney cancer is relatively new. This is largely due to the historical notion that renal cell carcinoma (RCC) is highly radioresistant.

SBRT for oligometastatic disease of mixed histologies has been shown to improve progression-free and even overall survival. A large cooperative group study recently demonstrated that there was no overall survival advantage seen when constrained to breast cancer alone.

HyTEC (Hypo-fractionated or “Hy”-dose per fraction, Treatment Effects in the Clinic) was an American Association of Physicists in Medicine-led initiative focusing on hypofractionated SBRT/SABR and stereotactic radiosurgery in adults.

When implementing newer technologies practices often rely on vendor training, an evaluation of published literature, and collaboration with others experienced in the technology. Incident learning has a critical role in radiation therapy and may be most important in new and emerging technologies.

Anal cancer rates are increasing, and there is a need to improve coordination across the spectrum of anal cancer care, from diagnosis, treatment, recovery and survivorship. Failure to understand the roles of all the multidisciplinary aspects of care leads to suboptimal patient care.  

Historically, the management of lymph node positive prostate cancer was limited to androgen deprivation therapy, but increasing data now support the use of multimodality therapy. As treatment options have expanded, patient-centered decision making has become increasingly complicated.

This session highlights the most clinically relevant abstracts within the Central Nervous System track of the 2023 ASTRO Annual Meeting scientific program.

Various advances in imaging are changing the clinical practice for Radiation Oncology.

One of the most exciting and rapidly evolving areas of radiation oncology is in its application to the settings of oligometastatic or metastatic disease. Some of the most significant progress has been in implementing local therapy in the management of oligometastatic NSCLC.